Description
DLin-MC3-DMA is one of the most utilized ionizable cationic lipids used for gene delivery in vivo. It is used to form liposomes, lipid nanoparticles (LNPs), and other related nanodelivery systems that can encapsulate siRNA, mRNA, plasmid DNA, or small molecules for delivery into the cytoplasm and for systemic administration of gene therapies. DLin-MC3-DMA was used in the first FDA approved RNAi treatment consisting of an siRNA targeted to hepatocytes for the treatment of polyneuropathy of hATTR amyloidosis in adults.